Literature DB >> 11490180

Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5'-nucleotidase activity in rats.

D R Lara1, M R Vianna, F de Paris, J Quevedo, J P Oses, A M Battastini, J J Sarkis, D O Souza.   

Abstract

In the search for differential mechanisms underlying clozapine's superior antipsychotic efficacy, the purinergic system has been considered, since an antagonist of the adenosine receptor A(2A) was shown to block clozapine acute effects on c-fos expression in rat striatum. Further investigating the interaction of clozapine with the purinergic system, we studied the effects of chronic treatment (28 days, intraperitoneal) with clozapine (25 mg/kg) and haloperidol (1.5 mg/kg) on the activity of ectonucleotidases in the striatum and hippocampus of rats. Clozapine selectively increased striatal 5'-nucleotidase activity (22%) compared to control and haloperidol groups. In vitro, neither drug affected enzyme activities. These results reinforce the differential effects of clozapine compared to haloperidol on the purinergic system. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11490180     DOI: 10.1159/000054925

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  9 in total

1.  Differential effects of clozapine and haloperidol on interval timing in the supraseconds range.

Authors:  Christopher J MacDonald; Warren H Meck
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

2.  Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain.

Authors:  Kelly Juliana Seibt; Renata da Luz Oliveira; Mauricio Reis Bogo; Mario Roberto Senger; Carla Denise Bonan
Journal:  Fish Physiol Biochem       Date:  2015-07-09       Impact factor: 2.794

3.  Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.

Authors:  Jie Zhang; Chadi G Abdallah; Junqing Wang; Xiaona Wan; Chunlian Liang; Liyun Jiang; Yuzhen Liu; Haixing Huang; Xiaohong Hong; Qingjun Huang; Renhua Wu; Chongtao Xu
Journal:  Psychiatry Res       Date:  2012-06-16       Impact factor: 3.222

4.  Biochemical and mass spectrometric characterization of soluble ecto-5'-nucleotidase from bull seminal plasma.

Authors:  Carlo Fini; Fabio Talamo; Silvia Cherri; Marcello Coli; Ardesio Floridi; Lino Ferrara; Andrea Scaloni
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

5.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 6.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 7.  Multiple Adenosine-Dopamine (A2A-D2 Like) Heteroreceptor Complexes in the Brain and Their Role in Schizophrenia.

Authors:  Dasiel O Borroto-Escuela; Luca Ferraro; Manuel Narvaez; Sergio Tanganelli; Sarah Beggiato; Fang Liu; Alicia Rivera; Kjell Fuxe
Journal:  Cells       Date:  2020-04-27       Impact factor: 6.600

Review 8.  Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging.

Authors:  Kavya Prasad; Erik F J de Vries; Philip H Elsinga; Rudi A J O Dierckx; Aren van Waarde
Journal:  Int J Mol Sci       Date:  2021-02-09       Impact factor: 5.923

Review 9.  Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.

Authors:  Silvia Pasquini; Chiara Contri; Stefania Merighi; Stefania Gessi; Pier Andrea Borea; Katia Varani; Fabrizio Vincenzi
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.